• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies appoints Claire Biot, Ph.D. to board of directors

Mauna Kea Technologies appoints Claire Biot, Ph.D. to board of directors

by Zina | Jul 23, 2020 | News

Mauna Kea Technologies announced today the appointment of Claire Biot, Ph.D., as an Independent Director, effective immediately. Dr Claire Biot is currently employed as Vice-President Life Science Industries at Dassault Systèmes, “the 3DEXPERIENCE...
Mauna Kea Technologies appoints Claire Biot, Ph.D. to board of directors

Mauna Kea Technologies reports second quarter and first half of 2020 sales

by Zina | Jul 20, 2020 | News

First Half of 2020 total sales down 47%; U.S. sales down 19%  Second Quarter total sales down 72%; U.S. sales down 47%  Sufficient liquidity to manage the business through the third quarter of 2021 READ THE COMPLETE PRESS RELEASE
Mauna Kea Technologies appoints Claire Biot, Ph.D. to board of directors

Mauna Kea Technologies announces further strengthening of financial condition by securing €4M of non-dilutive loans guaranteed by the French state (PGE)

by Zina | Jul 17, 2020 | News

Mauna Kea Technologies announced that it has received financing approvals from BNP Paribas and Bpifrance for a total of €4 million in non-dilutive financing in the form of French state-guaranteed loans (Prêts Garantis par l’Etat, or PGE in France)....
Mauna Kea Technologies appoints Claire Biot, Ph.D. to board of directors

Mauna Kea Technologies draws down the €6m second tranche of loan agreement with the European Investment Bank (EIB)

by Zina | Jul 6, 2020 | News

Mauna Kea Technologies announced it has drawn down the €6m second tranche of their €22.5 million loan agreement concluded on 20 June 2019 with the European Investment Bank.  The original loan agreement was signed in June 2019 and included an...
Mauna Kea Technologies Announces the Launch of a First in Human Study Combining Robotic Navigational Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy

Mauna Kea Technologies Announces the Launch of a First in Human Study Combining Robotic Navigational Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy

by Zina | Jun 24, 2020 | News

The Cellvizio® 100 series system with the AQ-Flex™ 19 Confocal Miniprobe™ will be used for the assessment of peripheral lung nodules    Mauna Kea Technologies today announced that, as part of its collaboration with the Lung Cancer...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}